Our study leads us to conclude that pre-existing TP53 mutations (i.e., loss of function) in hormone- dependent prostate cancer cells can contribute to the development of CRPC, likely via both facilitating the proliferation of and promoting the genomic instability in tumor cells. Here, TP53 is linked to prostate cancer.